Bile acid metabolism and signaling in liver disease and therapy

被引:69
作者
John Y.L.Chiang
机构
[1] DepartmentofIntegrativeMedicalSciences,CollegeofMedicine,NortheastOhioMedicalUniversity
关键词
D O I
暂无
中图分类号
R575 [肝及胆疾病];
学科分类号
100201 [内科学];
摘要
Bile acids play a critical role in the regulation of glucose, lipid, and energy metabolism through activation of the nuclear bile acid receptor farnesoid X receptor(FXR) and membrane G protein-coupled bile acid receptor-1(Gpbar-1, aka TGR5). Agonist activation of FXR and TGR5 improves insulin and glucose sensitivity and stimulates energy metabolism to prevent diabetes, obesity, and non-alcoholic fatty liver disease(NAFLD). Bile acids have both pro-and anti-inflammatory actions through FXR and TGR5 in the intestine and liver. In the intestine, bile acids activate FXR and TGR5 to stimulate fibroblast growth factor15 and glucagon-like peptide-1 secretion. FXR and TGR5 agonists may have therapeutic potential for treating liver-related metabolic diseases, such as diabetes and NAFLD.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 7 条
[1]
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis [J].
Kakiyama, Genta ;
Pandak, William M. ;
Gillevet, Patrick M. ;
Hylemon, Phillip B. ;
Heuman, Douglas M. ;
Daita, Kalyani ;
Takei, Hajime ;
Muto, Akina ;
Nittono, Hiroshi ;
Ridlon, Jason M. ;
White, Melanie B. ;
Noble, Nicole A. ;
Monteith, Pamela ;
Fuchs, Michael ;
Thacker, Leroy R. ;
Sikaroodi, Masoumeh ;
Bajaj, Jasmohan S. .
JOURNAL OF HEPATOLOGY, 2013, 58 (05) :949-955
[2]
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial [J].
Neuschwander-Tetri, Brent A. ;
Loomba, Rohit ;
Sanyal, Arun J. ;
Lavine, Joel E. ;
Van Natta, Mark L. ;
Abdelmalek, Manal F. ;
Chalasani, Naga ;
Dasarathy, Srinivasan ;
Diehl, Anna Mae ;
Hameed, Bilal ;
Kowdley, Kris V. ;
McCullough, Arthur ;
Terrault, Norah ;
Clark, Jeanne M. ;
Tonascia, James ;
Brunt, Elizabeth M. ;
Kleiner, David E. ;
Doo, Edward .
LANCET, 2015, 385 (9972) :956-965
[3]
Progressive Familial Intrahepatic Cholestasis [J].
Srivastava, Anshu .
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2014, 4 (01) :25-36
[4]
Gut microbiota and non-alcoholic fatty liver disease: new insights [J].
Aron-Wisnewsky, J. ;
Gaborit, B. ;
Dutour, A. ;
Clement, K. .
CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (04) :338-348
[5]
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid [J].
Hirschfield, Gideon M. ;
Mason, Andrew ;
Luketic, Velimir ;
Lindor, Keith ;
Gordon, Stuart C. ;
Mayo, Marlyn ;
Kowdley, Kris V. ;
Vincent, Catherine ;
Bodhenheimer, Henry C., Jr. ;
Pares, Albert ;
Trauner, Michael ;
Marschall, Hanns-Ulrich ;
Adorini, Luciano ;
Sciacca, Cathi ;
Beecher-Jones, Tessa ;
Castelloe, Erin ;
Boehm, Olaf ;
Shapiro, David .
GASTROENTEROLOGY, 2015, 148 (04) :751-U347
[6]
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease [J].
Mudaliar, Sunder ;
Henry, Robert R. ;
Sanyal, Arun J. ;
Morrow, Linda ;
Marschall, Hanns-Ulrich ;
Kipnes, Mark ;
Adorini, Luciano ;
Sciacca, Cathi I. ;
Clopton, Paul ;
Castelloe, Erin ;
Dillon, Paul ;
Pruzanski, Mark ;
Shapiro, David .
GASTROENTEROLOGY, 2013, 145 (03) :574-+
[7]
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity [J].
Mueller, Michaela ;
Thorell, Anders ;
Claudel, Thierry ;
Jha, Pooja ;
Koefeler, Harald ;
Lackner, Carolin ;
Hoesel, Bastian ;
Fauler, Guenter ;
Stojakovic, Tatjana ;
Einarsson, Curt ;
Marschall, Hanns-Ulrich ;
Trauner, Michael .
JOURNAL OF HEPATOLOGY, 2015, 62 (06) :1398-1404